DYNAMICS OF ADROPIN AND IRISIN BIOMARKERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND TYPE 2 DIABETES MELLITUS

summary. A pressing concern of modern medicine is the search for new biomarkers that can influence the development and course of acute myocardial infarction (AMI) in patents with type 2 diabetes mellitus (DM). The aim – To examine the dynamics of adropin and irisin serum levels in diabetic patients with or without AMI complications. Materials and Methods. In total, 134 AMI patients were enrolled. Among 60 examined AMI patients (group I), 41 patients were identified without early cardiovascular (CV) complications of AMI and 19 patients – with complicated AMI. Among 74 AMI patients with type 2 DM (group II), there were 48 patients without early AMI complications and 26 patients with early AMI complications. The control group consisted of 20 otherwise healthy persons. Serum levels of adropin and irisin were measured by enzyme-linked immunosorbent assay. Results. The adropin and irisin serum levels on day 1 of treatment was low in both nondiabetic (I) and diabetic patients (II) compared with those in the control group (p<0.05). On the 10th day of treatment, the levels of adropin in group II patients without early AMI complications were reduced by 13.91 % compared with those in group I (p<0.05). Group II with the presence of early AMI complications showed a reduction of 17.34 % in adropin levels on day 10 compared with group II (p<0.05). On day 10 of treatment, the irisin levels in group II without early AMI complications were reduced by 18.94 % compared with those in group I (p<0.05). In group II with the presence of early AMI complications on the 10th day, the irisin levels were reduced by 23.87 % compared with those in group I (p<0.05). Conclusions. The concentrations of adropin and irisin were significantly low in group II on day 1 and 10 of hospital stay. In the dynamics of treatment on day 10, the levels of adropin and irisin remained low in group II with early CV complications of AMI.